Blue Jet Healthcare
- Market cap
- ₹ 8,979 Cr.
- P/E
- 41.7x
- P/B
- 6.22x
- 52-week range
- 325 – 688.5
- ROE
- 20%
- ROCE
- 26%
- Dividend yield
- 0.3%
- Debt / equity
- 0.03
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Blue Jet Healthcare Limited is an India-based company. The Company is engaged in the business of manufacturing artificial sweeteners, contrast media intermediates, pharma intermediate, active pharmaceutical ingredients (APIs) used in pharmaceutical and healthcare products. It serves as a business-to-business company. Its integrated contrast media intermediate portfolio includes advanced intermediates for both iodine-based contrast agents used in X-ray and CT imaging, as well as gadolinium-based contrast agents used in MRI diagnostics. It manufactures saccharin and supplies to the healthcare, pharma, animal feed, food and beverages industries globally. It offers end-to-end integrated solutions from process development to commercialization of NCEs, advance intermediates, APIs and building blocks. Its expertise in Amino Acid-based derivatives develops and manufactures them on a small scale and is in the process of building multi-modular production blocks for large-scale manufacturing.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Blue Jet Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)41.7 against a typical 34.3: pricier than most peers (1st = cheapest).137th of 220
- Sales growth−17.5% against a typical +15.6% from a year earlier.173rd of 197
- Profit growth−14.3% against a typical +18.9% from a year earlier.111th of 160
- Share price, 3 months−14.2% against a typical −0.5%.163rd of 200
- Size₹ 8,979.2 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).43rd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | Withdrawn | — | 26 Oct 2026 |
Every agency has withdrawn its rating.
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 26 Oct 2026 | Withdrawn | — | Low | CARE | — | |
| 16 Dec 2025 | New rating | CARE A+ / CARE A1+ | — | CARE | ₹ 275 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 25 May 2026 | Financial Results/Dividend/Fund Raising | To consider and approve the financial results for the period ended March 31, 2026, dividend and Fund Raising |
| 13 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 4 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 22 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 14 May 2025 | Financial Results/Dividend/Fund Raising | To consider and approve the financial results for the period ended March 31, 2025, dividend and Fund Raising |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 | 165 | 192 | 235 | 293 |
| Expenses | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 234 | 111 | 146 | 163 | 195 |
| Operating Profit | 63 | 55 | 53 | 44 | 69 | 124 | 140 | 121 | 55 | 47 | 71 | 98 |
| OPM % | 35% | 33% | 29% | 27% | 33% | 39% | 41% | 34% | 33% | 24% | 30% | 33% |
| Other Income | 8 | −3 | 9 | 9 | 12 | 13 | 12 | 8 | 24 | 13 | 23 | 15 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 1 | 1 |
| Depreciation | 6 | 8 | 8 | 3 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 |
| Profit before tax | 64 | 44 | 54 | 49 | 77 | 132 | 147 | 123 | 69 | 54 | 87 | 106 |
| Tax % | 26% | 27% | 27% | 24% | 24% | 25% | 25% | 26% | 24% | 25% | 26% | 26% |
| Net Profit | 48 | 32 | 40 | 38 | 58 | 99 | 110 | 91 | 52 | 40 | 64 | 78 |
| EPS in Rs | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 | 4.51 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 14%
- 3 Years
- 10%
- TTM
- −28%
- 10 Years
- —
- 5 Years
- 12%
- 3 Years
- 16%
- TTM
- −34%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 26%
- 3 Years
- 24%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Blue Jet Healthcare | ₹ 517.40 | ₹ 8,979 Cr. | 41.7x | 6.2x | 20% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Akshay Bansarilal Arora
- Executive Chairman of the Board
- Ganesh Karuppannan
- Chief Financial Officer
- Vimalendu Kumar Singh
- Chief Operating Officer
- Sweta Poddar
- Compliance Officer, Company Secretary
- Shiven Akshay Arora
- Managing Director, Executive Director
- Popat Bhagwan Kedar
- Executive Whole-Time Director
- Naresh Suryakant Shah
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.